736
Views
2
CrossRef citations to date
0
Altmetric
Oncology

Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?

&
Pages 1453-1454 | Received 25 Mar 2016, Accepted 27 Apr 2016, Published online: 12 May 2016

References

  • Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol 2003;21:2138-46
  • Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553-61
  • Pinilla-Ibarz J, Cortes J. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer 2011;117:688-97
  • Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011;118:4554-60
  • Efficace F, Cardoni A, Cottone F, et al. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. Leuk Res 2013;37:206-13
  • Phillips KM, Pinilla Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 2013;21:1097-103
  • Hirji I, Gupta S, Goren A, et al. Chronic myeloid leukemia: association of treatment satisfaction, negative medication experience and treatment restrictions with health outcome, from patient’s perspective. Health Qual Life Outcomes 2013;11:167
  • Guerin A, Chen L, Ionescu-Ittu R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin 2014;30:2317-28
  • Kekale M, Peltoniemi M, Airaksinen M. Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence 2015;9:1733-40
  • Lutge I, Pfirrmann M, Stalljann I, et al. Health-related quality of life in CML patients under nilotinib first-line treatment: results of a German sub-study within the ENEST1st trial. Haematologica 2015;100(Suppl 1):abstract 233
  • Labeit AM, Copland M, Cork LM, et al. Assessment of quality of life in the NCRI Spirit 2 study comparing imatinib and dasatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Blood 2015;126:abstract 4024
  • Trask PC, Cella D, Besson N, et al. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res 2012;36:438-42
  • Whiteley J, Reismann A, Shapiro M, et al. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Curr Med Res Opin. 2016 May 5: 1-9. [Epub ahead of print]
  • Efficace F, Cocks K, Breccia M, et al. Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 2012;81:123-35

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.